Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

2(33.3%)

6Total

Phase 2(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06828861Phase 3Suspended

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

Role: lead

NCT07197034Phase 3Suspended

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

Role: lead

NCT06126653Phase 2Completed

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

Role: lead

NCT05153434Phase 2Completed

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Role: lead

NCT05215847Phase 2Completed

Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

Role: lead

NCT05121441Phase 2Completed

Study to Evaluate ARD-101 in Adults With Obesity

Role: lead

All 6 trials loaded